A groundbreaking clinical trial for China’s self-developed tuberculosis mRNA vaccine commenced on Monday at Beijing Chest Hospital, as reported by Beijing Evening News. This innovative vaccine boasts a protective efficacy over 20 times higher than traditional BCG and foreign tuberculosis vaccines, based on previous animal experiments.
The vaccine, which holds independent intellectual property rights, is poised to offer a new vaccination option for all age groups, effectively reducing tuberculosis incidence and infection. The research team will focus on studying immunization strategies, immune methods, administration routes, and vaccine adaptation symptoms.
In addition to the vaccine trial, Beijing Chest Hospital has also introduced an AI-powered diagnosis model and a rapid detection method for tubercle bacillus bacteria using tongue swabs. This diagnosis model enables remote, non-invasive early detection of pulmonary diseases, including tuberculosis, and is currently in the preclinical stage.
The rapid detection method is slated for gradual nationwide implementation starting July, marking a significant stride in tuberculosis diagnosis and treatment.